SCHEMBL1759463

SCHEMBL1759463

O=C(O)C1CC2CC2N1C(=O)O

nearest known ligand 0.54

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
ATM Q13315 1/20 0.31
DPP4 P27487 3/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26607531 1.00 ATM (0.31) ATMDPP4
SCHEMBL27156471 1.00 ATM (0.31) ATMDPP4
SCHEMBL30985474 1.00 ATM (0.31) ATMDPP4
SCHEMBL4102771 1.00 ATM (0.31) ATMDPP4
SCHEMBL31527632 1.00 ATM (0.31) ATMDPP4
SCHEMBL15145225 0.83 PIK3CA (0.33) DPP4
SCHEMBL3298331 0.83 PIK3CA (0.33) DPP4
SCHEMBL3298328 0.83 PIK3CA (0.33) DPP4
SCHEMBL26112319 0.83 PIK3CA (0.33) DPP4
SCHEMBL3511136 0.83 CFD (0.33) DPP4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4087583-B1 ARGINASE INHIBITORS AND METHODS OF USE MERCK SHARP & DOHME LLC (US) 2026-04-22 EP disclosed
WO-2025080589-A1 PROCESSES FOR PREPARING KRAS INHIBITORS INCYTE CORPORATION (US) 2025-04-17 WO disclosed
WO-2025080592-A1 COMBINATION COMPRISING A KRAS G12D INHIBITOR AND AN EGFR INHIBITOR FOR USE IN THE TREATMENT OF CANCER INCYTE CORPORATION (US) 2025-04-17 WO disclosed
WO-2025080585-A1 CRYSTALLINE FORMS OF 3-(1-(( 1 R,4R,5S)-2-AZABICYCLO[2.1.1 ]HEXAN-5-YL)-2-(( 1 R,3R,5R)-2-( CYCLOPROPANECARBONYL)-2-AZABICYCLO[3.1.0]HEXAN-3-YL)-7-(2,3-DICHLOROPHENYL)-6-FLUORO-4-METHYL-1 H-PYRROLO[3,2-C]QUINOLIN-8-YL)PROPANENITRILE INCYTE CORPORATION (US) 2025-04-17 WO disclosed
WO-2025080593-A1 COMBINATION THERAPY USING A KRAS G12D INHIBITOR AND PD-1 INHIBITOR OR PD-L1 INHIBITOR INCYTE CORPORATION (US) 2025-04-17 WO disclosed
WO-2023030385-A1 PYRIMIDINE-FUSED CYCLIC COMPOUND AND PREPARATION METHOD AND USE THEREOF 劲方医药科技(上海)有限公司 2023-03-09 WO disclosed
EP-4087583-A1 ARGINASE INHIBITORS AND METHODS OF USE Merck Sharp & Dohme LLC (US) 2022-11-16 EP disclosed
WO-2022228568-A1 PYRIDINO- OR PYRIMIDO-CYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF 劲方医药科技(上海)有限公司 2022-11-03 WO disclosed
EP-4053117-A1 ARYL, HETEROARYL, AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS Achillion Pharmaceuticals, Inc. (US) 2022-09-07 EP disclosed
EP-2499115-A1 HEPATITIS C VIRUS INHIBITORS Bristol-Myers Squibb Company (US) 2012-09-19 EP disclosed
WO-2011059850-A1 HEPATITIS C VIRUS INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2011-05-19 WO disclosed